Erythropoietin (EPO) plays a critical role in stimulating the proliferation and differentiation of erythroid precursor cells. EPO is heavily glycosylated with three asparagine (N)-linked tetraantennary oligosaccharides that may contain N-acetyllactosamine repeats and a single serine (0)-linked oligosaccharide. EPO expressed in Chinese hamster ovary cells exhibits biologic properties and amino acid and carbohydrate composition similar t o natural urinary EPO. The importance of the complex N-linked and the 0-linked carbohydrate was studied by expressing EPO in cells that are deficient in UDP-galactose/UDP-N-acetylgalactosamine 4-epimerase activity. In these cells, the ability to add galactose and N-acetylgalactosamine t o glycoproteins can be controlled by the addition of these sugars t o the culture medium. The results demonstrate that a block in 0-linked glycosylation and/or the ability t o process N-linked carbohydrate t o completion RYTHROPOIETIN (EPO) stimulates the prolifera-E tion and differentiation of erythroid precursor cells to more mature erythrocytes.' This glycoprotein is produced in the and circulates in the blood to stimulate erythropoiesis in the bone marrow. EPO is heavily glycosylated with one serine (0)-linked oligosaccharide and three asparagine (N)-linked oligosaccharides. The cDNA for EPO has been cloned'.' and expressed in Chinese hamster ovary (CHO) cells, CHO-derived EPO has been extensively characterized, both in amino acid and carbohydrate compos i t i~n .~?~ The N-linked oligosaccharides of recombinant EPO produced in CHO cell^^,^ as well as in baby hamster kidney cells" are mostly tetraantennary complex-type with N-acetyllactosamine repeats, similar to natural urinary EPO. The structure of the single 0-linked oligosaccharide has also been elucidated.8
does not alter EPO secretion. EPO produced without 0-linked carbohydrate exhibits normal in vitro and in vivo biologic activity and in vivo clearance. However, EPO produced with incompletely processed N-linked oligosaccharides exhibits normal m vitro activity but is at least 500-fold less effective in stimulating erythropoiesis in vivo. Studies on the survival of bioactive EPO remaining in the circulation demonstrated that EPO with incomplete N-linked oligosaccharides exhibits a sevenfold increased rate of clearance. However, this increased clearance may not fully account for the 500-fold loss of in vivo activity. These results suggest a potentially important unique requirement for appropriate complex N-linked oligosaccharides for the intrinsic biologic activity of EPO in vivo.
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hydrate addition and/or processing, or proteins expressed in either different cell types or in cell mutants with a defect in any of the glycosyltransferases." Removal of sialic acid from native''.14 and EPO increases its in vitro biologic activity, possibly by increasing its affinity to receptors on target cells. However, removal of sialic acid residues destroys the in vivo biologic activity of EPO, which correlates with its rapid clearance from the circulation by interaction with hepatic galactosyl Digestion of recombinant EPO with different glycosidases showed that the core portion of the N-linked oligosaccharides is required for full in vitro biologic activity."." Fractionation of recombinant EPO containing either biantennary and tetraantennary N-linked oligosaccharides demonstrated that EPO containing more extensively branched chains exhibits greater in vivo biologic activity, suggesting a possible unique role for the complex N-linked oligosaccharides in vivo. '' In this study we examine EPO produced with altered carbohydrate composition by expression of an EPO cDNA introduced into a mutant CHO cell line ldlD." The ldlD cells are deficient in UDP-galactose (UDP-Gal) and UDP-N-acetylgalactosamine (UDP-GalNAc) 4-epimerase activity. When these cells are propagated in medium with glucose as the only sugar source, the proteins produced have truncated N-linked and no 0-linked carbohydrate chains due to the inability of these cells to produce UDP-Gal or UDP-GalNAc from UDP-glucose or UDP-Nacetylglucosamine, respectively.2',22 All the defects in carbohydrate structure in these cells can be corrected by providing them with exogenous sources of Gal and GalNAc. An EPO expression vector was introduced into the ldlD cells to derive a cell line in which the extent of carbohydrate addition to EPO can be controlled by addition of Gal and/or GalNAc to the growth medium. This cell line has been used to study the effect of carbohydrate addition on the synthesis, processing, and secretion of EPO and the importance of carbohydrate for the in vitro and in vivo biologic activities of EPO.
IMPORTANCE OF CARBOHYDRATE IN EPO FUNCTION
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MATERIALS AND METHODS
Derivation of the EPO expression vector.
The EPO expression vector pEE4-11 contains the EPO cDNA' from the 5' untranslated region through the Bgl I1 site in the 3' untranslated region. It is contained on a Sal I fragment of approximately 800 bp and was cloned into the B o I site in the expression plasmid RK1-4.2' In pEE4-11, EPO expression is from the adenovirus major late promoter containing the SV40 enhancer element. The transcribed RNA contains the majority of the tripartite leader from adenovirus messenger RNAs (mRNAs), an intervening sequence, the EPO coding region, a dihydrofolate reductase (DHFR) coding region in the 3' end, and the SV40 polyadenylation signal.= ldlD-14 mutant CHO-K1 ~e l l s~' .~~ were maintained in Ham's F-12 medium (Hazelton, Denver, PA) containing penicillin (100 UimL), streptomycin (100 pg/mL), and glutamine (1 mmol/L) supplemented with 5% (volivol) fetal bovine serum (FBS; M.A. Bioproducts, Bethesda, MD) (complete medium). The EPO expression plasmid pEE4-11(20 kg), the DHFR expression plasmid 91023(B)24 (2 kg), and the G418 resistance plasmid pSV2NeoZS (2 pg) were coprecipitated with ethanol. Precipitated DNA was resuspended and a CaP0,-DNA precipitate prepared and introduced into ldlD cells as described.26 Two days later cells were subcultured 1:10 into Ham's F-12 lacking hypoxanthine and thymidine (Hazelton) with 10% (vol/vol) dialyzed FBS, 0.3 pmoliL methotrexate (MTX), 1 mg/mL G418 (GIBCO, Grand Island, NY), D (+) Gal (Sigma Chemical Co, St Louis, MO) (10 pmol/L), and GalNAc (Sigma Chemical Co) (100 pmoVL). After 10 days, one clone designated IdlD-A1 grew in this concentration of MTX and was further selected for resistance to 1.0 pmol/L MTX to amplify the copy number of the transfected DNA? 6 The cell line DN2-3 was previously derived by introducing the EPO cDNA expression vector into DHFR-deficient CHO cells (CHO DUKX-B11)6 by selection for DHFR expression and subsequent amplification by MTX resistance selection. DN2-3 produces 1,000 UimLid of EPO. The carbohydrate structure of EPO produced from DN2-3 cells has been extensively characterized.* For analysis of EPO expression, 1dID-A1 cells were propagated in Ham's F-12 medium with reduced FBS (1%) in the presence or absence of Gal and/or GalNAc (assay medium) for 48 hours. Cells were then rinsed with serum-free medium and fed with a reduced volume of the appropriate assay medium. Twenty-four hours later, conditioned medium was harvested and cell numbers counted by a Model ZM Coulter Counter (Luton, UK).
In vitro bioassay was as described." The assay is based on the ability of EPO to cause proliferation of cultured precursor cells derived from spleens of phenylhydrazine-injected mice quantitated by ['HI-thymidine uptake. The amount of observed proliferation is proportional to the amount of EPO in the test system.
In vivo bioassay was determined in the hypertransfused polycythemic mouse assay as previously described.28 EPO was infused twice over a 48-hour period and then 59Fe incorporation was measured over 3 days. The lower level of sensitivity of the assay is approximately 50 mU/mL.
Radiolabeling and immunoprecipitation. Logarithmically growing cells were fed medium containing Gal and/or GalNAc as described and 48 hours later approximately 3 x lo6 cells per 10-cm dish were labeled in 1 to 2 mL of methionine-free minimal essential medium (Flow, McLean, VA) containing 0. Approximately 8 X lo6 cells per 25-cm dish were labeled for 6 hours in 5 mL cysteine-free minimal essential medium (GIBCO) containing 1 mCi [%]-cysteine ( > 600 Ciimmol; DuPont-New England Nuclear), 0.5% (volhrol) FBS, l % aprotinin (Sigma Chemical Co) in the presence or absence of Gal (10 pmol/L) and/or GalNAc (100 pmoliL). Cells had previously been growing for 48 hours in the appropriate assay medium. Nine 25-cm dishes were labeled for each Gal and/or GalNAc condition. EPO was purified by chromatography as described.31 The elution of EPO protein was monitored by immunoprecipitation of column fractions with an anti-EPO mouse MoAb and SDS-polyacrylamide gel electrophoresis (SDS-PAGE), silver staining, and autoradiography. Analysis by silver staining demonstrated that all preparations of EPO were apparently homogeneous.
Clearance studies. For determination of recovery of in vitro biologic activity, conditioned medium samples were collected from LdlD-A1 cells propagated in the presence of Gal and GalNAc or the absence of Gal and GalNAc. Each sample was injected into three female Sprague-Dawley rats weighing 300 to 350 g and plasma samples were taken at the indicated times. EPO activity was determined by thymidine incorporation into cultured erythroid progenitor cells as described above.
The plasma clearance of "S-cysteine-labeled EPO was analyzed in four groups of rats. Each group of three animals received one of the four '%-labeled EPO preparations. The rats were anesthetized with a Ketamine and Xylazine mixture. Each animal then received an intravenous injection of the labeled sample at a dose level of approximately 0.5 pCi (approximately lo6 cpmipg). At the following intervals postinjection blood samples (150 pL) were taken by intracardiac puncture: 2,5, 15,45,90,300,600, and 1,440 minutes; and the serum was separated by centrifugation. Aliquots of the serum (50 pL) were counted in a liquid scintillation counter (Beckman LS7000). Greater than 95% of the counts detected were precipitable with trichloroacetic acid. The data are plotted as an average of the three animals that varied between 5% and 10% between animals. Aliquots of the plasma samples were also taken for immunoprecipitation using an antihuman EPO MoAb and analysis by SDS-PAGE.
The EPO biologic activity and counts remaining in the circulation for each group were averaged and these values were used to calculate the percent of the injected dose of counts or activity remaining at each time point. Plasma biologic activity and radioac-
Purification of [3sS]-cysteine-labeled EPO.
For personal use only. on June 6, 2017. by guest www.bloodjournal.org From tivity time curves were then constructed from these data and were fit to a biexponential function of the form:
Pharmacokinetic parameters were derived from the slopes and the intercepts of this function.'* The clearance was calculated as the initial dose divided by the area under the curve extrapolated to infinity. The initial volume of distribution was calculated as the dose divided by the plasma concentration at 0 time. The total volume of distribution was calculated as the dose divided by the area under the curve times 0.
RESULTS
Expression of EPO in ldlD cells.
The importance of Nand O-linked carbohydrate addition for EPO biosynthesis and activity was studied by expression of a cDNA encoding human EPO in ldlD CHO cells. These cells are deficient in the enzyme UDP-Gal and UDP-GalNAc 4-epimerase. When glucose is the only sugar source in the medium, this enzyme is required for the de novo synthesis of UDP-Gal and UDP-GalNAc. The defect in ldlD cells is reversed by the addition of Gal and GalNAc to the growth medium, which enables the synthesis of UDP-Gal and UDPGalNAc, respectively, to restore normal N-and 0-linked glycosylation. Without GalNAc in the growth medium, these cells are unable to synthesize mucin-type 0-linked carbohydrate addition because UDP-GalNAc is the first sugar added to the polypeptide backbone. Without Gal in the growth medium, both the N-linked and 0-linked oligosaccharides are truncated at the step of Gal addition because UDP-Gal is not available. The expected carbohydrate structures for the 0-linked and major tetraantennary N-linked oligosaccharides of EPO synthesized in ldlD CHO cells when propagated in the absence of Gal and/or GalNAc are shown in Fig 1. In the absence of GalNAc, there is only a defect in addition of GalNAc to serine residue 126. In the absence of Gal, addition of GlcNAcP1-2, GlcNAcP1-4, and GlcNAcP1-6 to mannose residues occurs to form bi-, tri-, and tetraantennary N-linked structures, but further addition of GalP1-4 and sialic acid (NeuNAc) as well as the N-acetyllactosaminyl repeats, of which the majority are present on the tetraantennary oligosaccharides,' does not occur. Also in the absence of Gal, the 0-linked oligosaccharide lacks the Galpl-3 and the sialic acid u2-6. In the presence of both Gal and GalNAc, fully glycosylated EPO is produced that should be similar to that previously characterized in detail.' ldlD cells were transfected with the EPO cDNA expression vector pEE4-11. Transformants were selected for resistance to G418 and low levels of methotrexate (0.3 pmol/L) and subsequently selected for higher MTX resistance. One cell line, designated IdlD-A1, is resistant to 1.0 pmol/L MTX and produces 600 to 900 U/mL/106 cells/d of EPO as determined by an in vitro bioassay (Materials and Methods).
The role of N-and 0-linked carbohydrate in the synthesis and secretion of EPO. To study the effects of N-and 0-linked glycosylation on the intracellular synthesis and secretion of EPO, the 1dlD-A1 cells were pulse-labeled with [35S]-methionine and then chased for increasing periods of time with unlabeled medium in the presence or absence of Gal and/or GalNAc. Cell extracts and conditioned medium were taken for EPO immunoprecipitation and analysis by SDS-PAGE. Analysis of the intracellular forms of EPO produced in either the presence or absence of Gal and/or GalNAc shows the primary translation product at 32 Kd detected after the 5-minute pulse label (Fig 2A, lanes 1, 6, 
-Gal
NeuNAcaP-3 (Galpl-4Gl~NAcpl-3)~.Galpl 74GlcNAcpl ' r 1 I, and la). Because thc prcscncc or absence of Gal andlor GalNAc docs not disturb the high mannosc corc oligosaccharidc, this precursor is thc samc size undcr all conditions. This spccics is proccsscd to a lower molccular wcight form (30 Kd) aftcr IS minutcs (Fig 2A, lancs 2, 7 , 12, and 17).
The incrcascd mobility likcly results from trimming of the high mannosc oligosaccharide corc. In the prcscncc of Gal (Fig 2A, lanc 7) or Gal and GalNAc (Fig 2A, lanc 17) it is possihlc to dctcct slowcr migrating EPO spccies as a smcar around 32 to 42 Kd. Thcsc spccics become more pronounccd with timc (Fig 2A. (Fig 2A, lancs 17 through 20) .
In thc abscncc of Gal, thc carbohydratc chains arc not fully proccsscd and the molecular wcight of thc protcin rcmains at 30 Kd (Fig 2A, lancs 2 through 5 and 12 through IS) . Undcr all conditions. EPO is cfiicicntly sccrctcd from thc ccll by 60 minutcs and is rccovcrcd in the conditioncd mcdium as a stahlc spccics. Complctcly glycosylatcd EPO was sccrcted as a hctcrogcncous smcar of 30 to 42 Kd (Fig  28, lancs 13 through 16) . Thc abscncc of GalNAc did not significantly alter the mobility or hctcrogcncity of thc sccrctcd EPO (Fig 2B, lancs S through 8) . Howcvcr, in thc abscncc of Gal, EPO was sccrctcd as a 30-Kd spccics ( Fig   2R. lancs 1 through 4 and 9 through 12) . A comparahlc pu1sckha.w using EPO producing CHO DUKX DN2-3 cclls showcd a vcry similar timc coursc for EPO sccrction.
Thcsc results dcmonstratc that cficicnt synthcsis. proccssing, and sccrction of EPO in thc IdlD-AI cclls is indcpcndcnt of thc prcscncc of cithcr complctc N-linkcd or 0-linkcd oligosaccharidcs.
To dcmonstratc that the diffcrcnccs in clcctrophorctic mobility of thc sccrctcd EPO observed above wcrc due to cxpcctcd diffcrenccs in carbohydrate addition, IdlD-AI cclls wcrc pulsc-labeled with ["S]-mcthioninc or ["SIcystcinc in thc prcscncc or absencc of Gal and GalNAc in thc mcdium as dcscribcd in Materials and Methods. Thc EPO was purificd from the labeled mcdium by either immunoprccipitation (Fig 3A) or conventional chromatography ( Fig 3B) and analyzed by gel electrophoresis before and aftcr N-g1ycana.w digcstion. Comparison of EPO purificd by cithcr mcthod yiclds the samc spcctrum of EPO polypcptidcs. N-glycanasc hydrolyzcs asparaginc-linked oligosaccharidcs from glycoproteins and lcavcs a frcc aspartic acid at thc glycosylation sitc." Fully glycosylatcd EPO produced from IdlD-AI cells in thc prcscncc of Gal and GalNAc migratcd its a hctcrogcncous spccics around 40 Kd ( Fig 3A, lanc I; Fig 3B. lanc 7) and yicldcd primarily a single band of 22 Kd on N-glycanasc digcstion and a minor spccics at 21 Kd (Fig 3 4 lanc 2; Fig 3B, lanc 8 spccics most likely has no attached oligosaccharides and rcprcsents a proportion of EPO that is not 0-linkcd glycosylated. EPO produccd in thc prcscncc of Gal alonc is digcstcd to the 21-Kd spccics aftcr trcatmcnt with N-glycanasc ( Fig 3B, lanc 4) . consistent with the lack of 0-linked oligosaccharidc. EPO produccd in thc prcscncc of GalNAc alonc is primarily digcstcd to a spccics migrating with a mobility bctwccn thc 21 -and 22-Kd spccics (Fig 3B, lanc 6 ).
likcly rcprcscnting EPO containing an 0-linkcd GalNAc but lacking GalpI-3 and sialic acid. €PO produccd in the abscncc of Gal and GalNAc migrates at 30 Kd ( Fig 3A, lanc  3 ; Fig 3B lanc 1) and aftcr digcstion with N-glycanasc ( Fig  3A, lanc 4 ; Fig 3B lanc 2) incrcascs in mobility to thc 21-Kd form that lacks all N-linkcd and 0-linkcd carbohydratc. Thc 21-Kd spccics occurs whcncvcr 0-linkcd glycosylation is blockcd (Fig 3B, lancs 2 and 4) . The diffcrcncc in clcctrophorctic mobility of the N-glycanase-trcatcd samplcs of EPO synthcsizcd in thc prcscncc comparcd with thc abscncc of GalNAc is approximatcly 1 to 2 Kd, which can bc attributcd to thc molccular mass of a single 0-linkcd oligosaccharidc prcscnt on EPO." Thc prcscncc of 0-linked oligosaccharidc on EPO was confirmcd by labcling IdlD-AI cclls for 4 hours with ['HI-Gal in thc prcscncc or abscncc of GalNAc in the culturc medium. Labclcd medium samplcs wcrc immunoprccipitatcd and analyzcd by clcctrophorcsis on SDSpolyacrylamidc gels bcforc and aftcr N-glycanasc digcstion. EPO from cclls labclcd with ['HI-Gal in thc prcscncc of GalNAc (Fig 3A, lanc 5 ) comigratcs with thc ["SImcthioninc-labclcd fully glycosylatcd EPO (Fig 3A, lanc  I) . Following N-glycanasc digcstion of 'H-Gal-labclcd €PO. most of thc radioactivity is lost on rcmoval of thc N-linked oligosaccharidcs. Howcvcr, a faint band can be dctcctcd at 22 Kd comigrating with thc ["SI-mcthioninclabclcd spccics (Fig 3A. lanc 6) . By contrast, whcn cclls arc labclcd with ['HI-Gal in thc abscncc of GalNAc, which prcvcnts 0-linkcd glycosylation, digcstion with N-glycanasc ncvcr showcd a dctcctablc [ 'HI-Gal-labclcd spccics. Thcsc rcsults dcmonstratc that thcrc is no dctcctablc 0-linkcd oligosaccharidc on this protcin exprcsscd in thc abscncc of GsINAc. Thus, the data in Figs 2 and 3 show that thc IdlD-AI cclls arc capablc of synthesizing EPO with varying carbohydratc chains of the cxpcctcd composition solcly dcpcndcnt on thc addition of Gal and/or GalNAc to thc culturc medium.
Biologic activity of EPO with altewd carhohydmte composition. To cxaminc thc cffcct of altcrcd carbohydratc composition on thc biologic activity of EPO, "S-cystcinclabclcd conditioncd medium from IdlD-AI cells growing in thc prcsencc or abscncc of Gal andlor GalNAc was prcparcd and thc EPO purificd to homogcncity for bioassay in vitro and in vivo. Thc rcsults arc summarized in Tablc 1. For quantitation, thc in vitro activity was normalized to cpm of "S-labclcd protcin. Thc rcsults in Tablc 1 mcasurc thc ability for EPO to stimulate prolifcration of crythroid progcnitor cclls. The rcsults show that in vitro activity of sccrctcd EPO was not affcctcd by thc prcsencc or abscncc of GalNAc in thc conditioned medium. In contrast, €PO synthcsizcd in the abscncc of Gal cxhibitcd a twofold to thrccfold incrcasc in activity comparcd with EPO synthcsizcd in thc prcscncc of Gal. Thcsc rcsults dcmonstratc that thc prcscncc of 0-linkcd oligosaccharides do not dctcctably influcncc EPO activity in vitro, whcrcas truncation of the For personal use only. on June 6, 2017. by guest www.bloodjournal.org From N-linked oligosaccharides by omission of Gal actually results in increased activity in vitro. This increase is consistent with previous findings that removal of sialic acid may increase the interaction of EPO with its re~eptor.'"~~ By contrast, the different forms of IdlD-A1 EPO protein exhibited dramatically different activities in the in vivo bioassay. EPO with full N-linked and 0-linked carbohydrate (+ Gal and + GalNAc) or full N-linked without 0-linked carbohydrate (+ Gal and -GalNAc) exhibited similar specific activities. However, the activity of 1dlD-A1 EPO with truncated N-linked oligosaccharides (-Gal with or without GalNAc) was reduced two to three orders of magnitude in this assay. In another experiment, infusion of a large dose of purified EPO (70 U based on in vitro bioactivity) prepared in the absence of Gal and GalNAc yielded 80 mU of activity above a background of 50 mU in this assay. We do not know if this low level of activity results from a trace level of fully glycosylated EPO not detectable in the sample. These results demonstrate that truncation of the N-linked oligosaccharides reduces in vivo biologic activity at least 500-fold. Although the data shown in Table  1 were obtained by subcutaneous injection of EPO samples, similar results were obtained by intravenous infusion (data not shown). These results show that the different forms of EPO were active in vitro with roughly similar specific activities but only the EPO proteins with complete N-linked glycosylation were active in vivo.
Clearance of IdlD-A1 EPO proteins in a rat model system. To determine if a reduction in the plasma half-life was responsible for the loss of in vivo activity of EPO containing truncated N-linked oligosaccharides, the in vivo clearance of EPO in a rat model system was studied. Conditioned medium from 1dlD-A1 cells propagated in the presence or absence of Gal and GalNAc was harvested and injected into rats as described in Materials and Methods. At the indicated times, pIasma samples were taken for assay of in vitro biologic activity. The results show that EPO prepared in the absence of Gal and GalNAc exhibits a fivefold increased T1/2@ and an approximately sevenfold increased rate of clearance (Fig 4A and Table 2A ). These results show that EPO with truncated N-linked oligosaccharides is not inactivated on injection into the rat. The sevenfold difference in clearance cannot fully account for the 500-fold reduction in the in vivo specific activity and suggests that N-linked carbohydrate is not required to interact with the EPO receptor in vitro but may be required in vivo.
To characterize the differences in clearance in greater detail, [35S]-cysteine-labeled EPO was prepared in the presence and/or absence of Gal and/or GalNAc and purified for clearance studies (see Materials and Methods and Fig 3B) . EPO prepared in the absence of Gal exhibits an approximately twofold greater volume of distribution for the @-phase compared with EPO prepared in the presence of Gal (Table 2B) . EPO prepared in the absence of Gal exhibited an initial rapid clearance and a twofold increase in clearance compared with fully glycosylated EPO. The integrity of infused EPO remaining in the circulation was qualitatively analyzed by immunoprecipitation of plasma samples taken at different times postinjection and SDS-PAGE of the immunoprecipitates. The results show that EPO prepared in the absence of Gal is detected intact in the circulation at 90 minutes postinjection (Fig 4C) . However, the loss of radiolabeled EPO from the plasma samples by this qualitative analysis appears to more closely parallel the results from the clearance of EPO biologic activity. The total clearance of EPO with partial N-linked glycosylation (-Gal/-GalNAc) was increased sevenfold by in vitro bioassay and twofold by plasma radioactivity compared with fully glycosylated EPO. The difference in clearance from these two studies likely results from reutilization of 3sS-cysteine in the metabolic-labeled EPO studies. Recent studies have shown significant reutilization of radiolabeled amino acids can occur and be incorporated into plasma protein (D. Liberato, personal communication, February 1991). Reutilization of 35S-cysteine may account for the longer Tl/2@ for EPO with partial N-linked glycosylation observed in Table 2B compared with Table 2A . Consistent with this interpretation is the observation that immunoprecipitation of EPO from plasma samples (Fig 4C) qualitatively yields results similar to those obtained from the clearance of EPO biologic activity. For this reason, we believe the sevenfold difference observed in Table 2A is more reflective of the actual difference in clearance between these two forms of EPO. At this time further studies are required to evaluate the complex pharmacokinetic parameters of these forms of EPO in the rat. However, these results do demonstrate that EPO with truncated N-linked oligosaccharides in the absence of a penultimate Gal residue is cleared at a greater rate than fully glycosylated EPO. In addition, the sevenfold difference in clearance may not account for the 500-fold difference in in vivo biologic activity.
DISCUSSION
We have studied the importance of carbohydrate addition for EPO secretion and biologic activity by expression of EPO in the ldlD CHO cell line. In the ldlD cells it is Thc addition and proccssing of oligosaccharide chains on a protein may effect the cfficicnt intraccllular routing and sccrction of that protein. Inhibition of N-linkcd glycosylation by tunicamycin blocks sccrction of EPO from HcpG2 and CHO CCIIS.~ Our rcsults show that ncithcr the incomplctc processing of N-linkcd oligosaccharides by prcvcnting addition of Gal, and thus prcsumably polylactosaminc and sialic acid, nor thc inability to add 0-linkcd oligosaccharides influcnccs thc cficicncy or ratc of sccrction of EPO. Thus, ncithcr of thcsc stcps arc obligatory for cfficicnt sccrction of EPO in CHO cells. Thcsc observations arc similar to thosc found for human chorionic gonadotropin" and apolipoprotcin E' cxprcsscd in ldlD cclls. In contrast, whcn thc scrinc at thc sitc of 0-glycosylation was changcd to a glycinc to block 0-glycosylation, thc cxprcsscd EPO was not sccrctcd." Thc rcsults prcscntcd hcrc show that For personal use only. on June 6, 2017. by guest www.bloodjournal.org From native EPO can be efficiently secreted in the absence of 0-linked glycosylation. This finding suggests that the serine to glycine change altered the folding and/or stability of the mutant protein.
The biologic activities of EPO proteins containing different extents of carbohydrate addition were monitored by in vitro and in vivo bioassay systems. The in vitro assay measures the ability of EPO to stimulate the proliferation of erythroid progenitor cells isolated from mouse bone marrow and cultured in vitro. EPO containing or lacking 0-linked oligosaccharides displayed similar specific activities when monitored by this in vitro bioassay. Thus, the interaction of EPO with the hematopoietic target cells is not dependent on the presence of 0-linked oligosaccharide chains. This finding is in agreement with recent studies using glycosidase treatment of recombinant EP0. 19 We observed a twofold to threefold increase in the specific activity of EPO prepared with truncated N-linked oligosaccharides. This finding is consistent with other observations on a~ialo-EP0.'~"~ The in vivo assay measures the ability of EPO to stimulate erythropoiesis when infused into a polycythemic mouse. The absence of 0-linked oligosaccharides did not influence the in vivo biologic activity of EPO. By contrast, the in vivo activity of EPO with truncated N-linked oligosaccharides was reduced 500-fold.
To provide insight to the potential reason for the negligible in vivo activity of the EPO with truncated N-linked oligosaccharides, we studied the plasma clearance of the EPO proteins containing different extents of carbohydrate addition. Sialic acid residues attached to complex-type N-linked oligosaccharides are indispensible for the survival of glycoproteins in the circulation. Once sialic acid is removed, the exposed Gal residues may facilitate binding and internalization of the glycoprotein by the Gal binding receptor on Studies performed with asialodemonstrate that the sialic acid residues attached to the EPO polypeptide are not required for the hormone's in vitro interaction with its receptor, but are essential for in vivo biologic activity. The loss of in vivo biologic activity was correlated with a rapid clearance presumably mediated by the Gal binding receptor in the liver. The expression of EPO in the ldlD cells has allowed the analysis of EPO that lacks both the sialic acid and Gal residues. This EPO exhibited a sevenfold increased rate of clearance. The increased clearance may be attributable to tendency of deglycosylated EPO to aggregate,14 the twofold increased volume of distribution, or possibly to endocytosis of N-acetylglucosamine terminated glycoproteins by the N-acetylglucosamine receptors present in hepatic reticuloendothelial cells and macrophage^.'^,^ In contrast to previous studies that demonstrated that asialo-EPO was not detectable in the circulation after 6 m i n~t e s , '~ the EPO containing truncated N-linked oligosaccharides was detectable in the circulation at 90 minutes postinjection. The presence of this EPO in the circulation after 90 minutes suggests that the absence of Gal allows the protein to escape clearance by the hepatocyte. The apparent differences in clearance of asialo-EPO and our truncated N-linked oligosaccharide EPO may reflect the efficiency by which Gal and N-acetylglu-~~0 1 2 -1 6 cosamine terminated proteins undergo endocytosis by their respective receptors. The approximately sevenfold increase in clearance observed for EPO prepared in the absence of Gal may not fully account for the 500-fold reduction in biologic activity. Plasma samples taken from rats infused with the different forms of EPO displayed in vitro activity, thus demonstrating functional activity of the protein in the plasma. Although the in vivo bioassays were performed with mice and the clearance studies with rats, we think it unlikely that species differences may account for the observed results. From the results of our studies it seems possible that complete N-linked oligosaccharides are required for the intrinsic biologic activity of EPO in vivo. However, due to the complexity of the in vivo biologicactivity assay and pharmacokinetics of EPO, further detailed studies are required to identify their specific role.
Our studies suggest that, in addition to protection from clearance by the hepatic galactosyl receptor, some property of the N-linked carbohydrate is required for the in vivo activity of EPO. This finding is consistent with the observation that tetraantennary oligosaccharide containing EPO exhibits a sevenfold greater specific activity in vivo than biantennary oligosaccharide containing EPO." It is possible that the N-linked carbohydrate may influence the bioavailability of EPO in vivo in such a way that is not detected in the in vitro assay. Polylactosamine repeats are present on the tetraantennary N-linked oligosaccharides of EP0.8 It is interesting to speculate that these repeats, which are absent on the EPO produced by ldlD cells in the absence of Gal, may be important specificity determinants in the in vivo accessibility andlor in vivo binding of the hormone to erythroid progenitor cells.
Several of the natural hematopoietins, including EPO, are extensively glycosylated. Genetic engineering has enabled production of large quantities of these hormones that are very similar in structure to that derived from the natural source. To use these engineered molecules as therapeutic agents it may be most beneficial to elucidate the function of the carbohydrate structure of these glycoproteins. The ldlD cells have allowed us to produce and examine the biologic activities of EPO proteins with altered carbohydrate composition. The intracellular processing and secretion of EPO, its in-vitro bioassay activity, and its in vivo clearance are independent of 0-linked glycosylation and complete N-linked glycosylation. However, its in vivo bioactivity is dependent on complete N-linked glycosylation, pointing to a role of the unusual polylactosamine repeats of the tetraantennary oligosaccharides for some vital function in this activity. The determination of the most active glycosylated forms of a recombinant protein may be very important to the future application of the molecule as a therapeutic agent.
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